<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04560582</url>
  </required_header>
  <id_info>
    <org_study_id>NEPH-2018-27080</org_study_id>
    <nct_id>NCT04560582</nct_id>
  </id_info>
  <brief_title>Immunosuppression Reduction in Failed Allograft Guided by cfDNA</brief_title>
  <official_title>Immunosuppression Reduction in Failed Allograft Guided by cfDNA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal timing for immunosuppression tapering for patients with failed kidney transplant&#xD;
      is not known. This pilot study would be to correlate rise in cf-DNA and increase in cPRA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational cohort study collecting data and blood specimens at designated time&#xD;
      points. The primary outcome will be comparing the cPRA in patients that have a rise in cf-DNA&#xD;
      to those that do not have a rise in cf-DNA. Seondary outcomes include comparison of the&#xD;
      combined incidence of need for transfusion, need for methylprednisolone and allograft&#xD;
      nephrectomy, ESA dose, allograft tenderness, and gross hematuria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cPRA Concentrations</measure>
    <time_frame>1 day</time_frame>
    <description>Outcome is reported as the serum concentration of calculated Panel Reactive Antibody (cPRA) at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cf-DNA Concentrations</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Outcome is reported as the serum concentration of circulating-free DNA (cfDNA) at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, and 24 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Need for Transfusion</measure>
    <time_frame>24 weeks</time_frame>
    <description>Outcome is reported as the percent of participants who require transfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Need for Methylprednisolone and Allograft Nephrectomy</measure>
    <time_frame>24 weeks</time_frame>
    <description>Outcome is reported as the percent of participants who require methylprednisolone and allograft nephrectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ESA Dose</measure>
    <time_frame>24 weeks</time_frame>
    <description>Outcome is reported as the percent of participants who require a erythropoesis stimulating agent (ESA) dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Allograft Tenderness</measure>
    <time_frame>24 weeks</time_frame>
    <description>Outcome is reported as the percent of participants who experience allograft tenderness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Gross Hematuria</measure>
    <time_frame>24 weeks</time_frame>
    <description>Outcome is reported as the percent of participants who experience gross hematuria.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Kidney Transplant; Complications</condition>
  <condition>Kidney Transplant Rejection</condition>
  <condition>Kidney Transplant Failure</condition>
  <arm_group>
    <arm_group_label>Kidney Transplant Patients with Failed Allograft</arm_group_label>
    <description>All participants are assigned to a single cohort of kidney transplant patients with failed allograft requiring dialysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <description>Participants will have blood drawn for analysis at baseline and every 4 weeks for a total of 7 blood draws over 24 weeks.</description>
    <arm_group_label>Kidney Transplant Patients with Failed Allograft</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Specimens will be stored by study code. All study data will be associated with the specimen&#xD;
      through the study code link.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study proposes to recruit adult patients primarily from the inpatient units at UMMC&#xD;
        Fairview, or the Renal or Transplant facilities at the Clinics and Surgery Center as&#xD;
        attended by the PI and Co-Is. Additional clinics will be recruited from depending on&#xD;
        patient population and clinician support.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Failed allograft requiring dialysis&#xD;
&#xD;
          -  Urine output less than 500 cc/day&#xD;
&#xD;
          -  No living donor available for re-transplant option or anticipated deceased donor&#xD;
             within the next 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - cPRA at entrance of 100%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samy Riad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minenesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samy Riad, MD</last_name>
    <phone>612-624-9444</phone>
    <email>riad005@umn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ghislaine Feussom</last_name>
    <phone>612-626-3636</phone>
    <email>feuss001@umn.edu</email>
  </overall_contact_backup>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

